BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 14668690)

  • 1. Lipid abnormalities in insulin resistant states.
    Watson KE; Horowitz BN; Matson G
    Rev Cardiovasc Med; 2003; 4(4):228-36. PubMed ID: 14668690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dyslipidemia in type 2 diabetes.
    Krauss RM; Siri PW
    Med Clin North Am; 2004 Jul; 88(4):897-909, x. PubMed ID: 15308384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Dyslipidemia in diabetes mellitus].
    Niemeijer-Kanters SD; Banga JD; Erkelens DW
    Ned Tijdschr Geneeskd; 2001 Apr; 145(16):769-74. PubMed ID: 11346913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease.
    Staels B; Maes M; Zambon A
    Nat Clin Pract Cardiovasc Med; 2008 Sep; 5(9):542-53. PubMed ID: 18628776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacologic treatment of type 2 diabetic dyslipidemia.
    Moon YS; Kashyap ML
    Pharmacotherapy; 2004 Dec; 24(12):1692-713. PubMed ID: 15585439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin resistance, the insulin resistance syndrome, and cardiovascular disease.
    Reaven GM
    Panminerva Med; 2005 Dec; 47(4):201-10. PubMed ID: 16489319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The lipid triad in type 2 diabetes - prevalence and relevance of hypertriglyceridaemia/low high-density lipoprotein syndrome in type 2 diabetes.
    Temelkova-Kurktschiev T; Hanefeld M
    Exp Clin Endocrinol Diabetes; 2004 Feb; 112(2):75-9. PubMed ID: 15031770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intensive insulin therapy reduces small dense low-density lipoprotein particles in patients with type 2 diabetes mellitus: relationship to triglyceride-rich lipoprotein subspecies.
    Hayashi T; Hirano T; Yamamoto T; Ito Y; Adachi M
    Metabolism; 2006 Jul; 55(7):879-84. PubMed ID: 16784958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
    Van Ganse E; Laforest L; Burke T; Phatak H; Souchet T
    Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diabetic dyslipidemia: a case for aggressive intervention in the absence of clinical trial and cost effectiveness data.
    Lewis GF
    Can J Cardiol; 1995 May; 11 Suppl C():24C-28C. PubMed ID: 7750045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal lipid screening and use of lipid-lowering medications in pediatric type 1 diabetes.
    Maahs DM; Wadwa RP; McFann K; Nadeau K; Williams MR; Eckel RH; Klingensmith GJ
    J Pediatr; 2007 Feb; 150(2):146-50, 150.e1-2. PubMed ID: 17236891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid disorders in type 2 diabetes.
    Braun LT
    Nurs Clin North Am; 2001 Jun; 36(2):291-302, vii. PubMed ID: 11382564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dyslipidaemia and coagulation defects of insulin resistance.
    Frohlich J; Steiner G
    Int J Clin Pract Suppl; 2000 Oct; (113):14-22. PubMed ID: 11965826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statins and diabetes.
    Carmena R; Betteridge DJ
    Semin Vasc Med; 2004 Nov; 4(4):321-32. PubMed ID: 15861314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reducing cardiovascular complications of type 2 diabetes by targeting multiple risk factors.
    Reasner CA
    J Cardiovasc Pharmacol; 2008 Aug; 52(2):136-44. PubMed ID: 18670366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postprandial lipemia: an under-recognized atherogenic factor in patients with diabetes mellitus.
    Pastromas S; Terzi AB; Tousoulis D; Koulouris S
    Int J Cardiol; 2008 May; 126(1):3-12. PubMed ID: 17689745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low- and high-density lipoprotein cholesterol goal attainment in dyslipidemic women: The Lipid Treatment Assessment Project (L-TAP) 2.
    Santos RD; Waters DD; Tarasenko L; Messig M; Jukema JW; Ferrières J; Verdejo J; Chiang CW;
    Am Heart J; 2009 Nov; 158(5):860-6. PubMed ID: 19853709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C.
    Chapman MJ; Assmann G; Fruchart JC; Shepherd J; Sirtori C;
    Curr Med Res Opin; 2004 Aug; 20(8):1253-68. PubMed ID: 15324528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging therapeutic strategies for the management of dyslipidemia in patients with the metabolic syndrome.
    Davidson MH
    Am J Cardiol; 2004 Jun; 93(11A):3C-11C. PubMed ID: 15178511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial).
    Goldenberg I; Benderly M; Sidi R; Boyko V; Tenenbaum A; Tanne D; Behar S
    Am J Cardiol; 2009 Jan; 103(1):41-5. PubMed ID: 19101227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.